Immunohistochemical staining of the 38 clinical samples confirmed a different level of LILRB1 expression in tumor tissues in different glioma grades (Fig. 3A) and the LILRB1 expression increased with rising glioma pathological grade (Fig. 3B). This evidence concerns the gene LILRB1 and neoplasm.